bispecific antibody


Also found in: Wikipedia.

bispecific antibody

1. an antibody having specificity for a target cell on one arm and for a treatment or killing agent on the other.
See also: bivalent antibody.
2. synthetic antibody constructed by cross-linking Fab fragments from separate monoclonal antibodies.

bispecific antibody

Immunology
An antibody or an antiserum raised against two antigens or proteins on the surface of different cells.

Molecular biology
A bioengineered antibody with 2 different binding sites that recognise 2 different antigens.
References in periodicals archive ?
Zymeworks' lead clinical candidate, ZW25, is a novel Azymetric bispecific antibody currently in Phase 2 clinical development.
On the other hand, bispecific antibody also shows a promising effect in the field of gene therapy, developed as an adapter molecule to recognize the vector and a specific marker on target cell surface, insuring against modification of the virus and disruption of vector assembly, stability, or activity.
Aptevo Therapeutics announced that it has completed dosing in a single ascending dose, or SAD, Phase 1 study of APVO210, a novel investigational bispecific antibody candidate being developed for the treatment of autoimmune diseases.
Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment, while avoiding the systemic immunosuppression of conventional medicines.
M2 EQUITYBITES-April 24, 2019-Innovent treats first patient with advanced malignancy under the Phase I clinical trial of IBI318 bispecific antibody in China
Global Banking News-April 24, 2019-Innovent treats first patient with advanced malignancy under the Phase I clinical trial of IBI318 bispecific antibody in China
have restructured their global discovery and development agreement for new immuno-oncology cancer treatments, providing for ongoing collaborative development of two clinical-stage bispecific antibody programs.
They wondered if there was a way to create a bispecific antibody not from fragments, but from 2 complete half-antibodies.
The new compound will be based on Genmab's bispecific antibody technology DuoBody and a novel ADC technology from the partner.
They also created a second bispecific antibody aimed at additional targets.
As a result, when a bispecific antibody complex binds to healthy tissue away from light, it cannot activate T-cells.